Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cellengene Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, so the prosecution setting is fully concentrated.
DRISCOLL, MAUREEN VARINA is the busiest examiner, with 1 pending matter. Counsel can focus review on that examiner, the applicable art unit, and the specific biotechnology issues presented in the single active matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, MAUREEN VARINA | 1 | 65.3% | +41.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19124680 | CHIMERIC ANTIGEN RECEPTOR WITH INCREASED AFFINITY FOR MESOTHELIN AND USE THEREOF | DRISCOLL, MAUREEN VARINA | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19124680 | CHIMERIC ANTIGEN RECEPTOR WITH INCREASED AFFINITY FOR MESOTHELIN AND USE THEREOF | DRISCOLL, MAUREEN VARINA | 1644 | §112 | Non-Final OA | — | Pending | Apr 25, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCellengene Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Maureen Varina Driscoll has the most, with 1 of Cellengene Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.